A new therapeutic avenue for bronchiectasis : dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart

A new therapeutic avenue for bronchiectasis : dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart

Non-cystic fibrosis bronchiectasis (NCFB) characterized by permanent bronchial dilatation and recurrent infections has been clinically managed by long-term intermittent inhaled antibiotic therapy among other treatments. Herein we investigated dry powder inhaler (DPI) formulation of ciprofloxacin (CI...

Full description

Saved in:
Bibliographic Details
Main Authors: Tran, The-Thien, Vidaillac, Celine, Yu, Hong, Yong, Valerie Fei Lee, Roizman, Dan, Chandrasekaran, Ravishankar, Lim, Albert Yick Hou, Low, Teck Boon, Tan, Gan Liang, Abisheganaden, John A., Koh, Mariko Siyue, Teo, Jeanette, Chotirmall, Sanjay Haresh, Hadinoto, Kunn
Other Authors: School of Chemical and Biomedical Engineering
Format: Article
Language:English
Published: 2020
Subjects:
Engineering::Bioengineering
Bronchiectasis
Ciprofloxacin
Online Access:https://hdl.handle.net/10356/137077
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English

Internet

https://hdl.handle.net/10356/137077

Similar Items